{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T01:09:15Z","timestamp":1790989755825,"version":"4.1.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.biopha.2016.05.049","type":"journal-article","created":{"date-parts":[[2016,6,22]],"date-time":"2016-06-22T16:06:28Z","timestamp":1466611588000},"page":"58-63","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"special_numbering":"C","title":["Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis"],"prefix":"10.1016","volume":"83","author":[{"given":"Li","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chongjuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2016.05.049_bib0005","first-page":"212","article-title":"Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths","volume":"61","author":"Siegel","year":"2011","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2016.05.049_bib0010","first-page":"277","article-title":"Cancer statistics, 2010","volume":"60","author":"Jemal","year":"2010","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.biopha.2016.05.049_bib0015","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1093\/jnci\/djp450","article-title":"Designing early detection programs for ovarian cancer","volume":"102","author":"Hartge","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2016.05.049_bib0020","doi-asserted-by":"crossref","first-page":"740472","DOI":"10.1155\/2010\/740472","article-title":"Targeted therapy in ovarian cancer","volume":"2010","author":"Willmott","year":"2010","journal-title":"J. Oncol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0025","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.cca.2012.10.058","article-title":"Detection and monitoring of ovarian cancer","volume":"415","author":"Su","year":"2013","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.biopha.2016.05.049_bib0030","first-page":"325","article-title":"Prognostic factors in early-stage ovarian cancer","volume":"7","author":"Tognon","year":"2013","journal-title":"Ecancermedicalscience"},{"key":"10.1016\/j.biopha.2016.05.049_bib0035","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","article-title":"MicroRNAs: genomics, biogenesis, mechanism, and function","volume":"116","author":"Bartel","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2016.05.049_bib0040","doi-asserted-by":"crossref","first-page":"14785","DOI":"10.3390\/ijms140714785","article-title":"Extracellular microRNAs in urologic malignancies: chances and challenges","volume":"14","author":"Huang","year":"2013","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2016.05.049_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/bjc.2015.168","article-title":"MiR-320e is a novel prognostic biomarker in colorectal cancer","volume":"113","author":"Perez-Carbonell","year":"2015","journal-title":"Br. J. Cancer"},{"issue":"8","key":"10.1016\/j.biopha.2016.05.049_bib0050","doi-asserted-by":"crossref","DOI":"10.1007\/s10571-015-0210-x","article-title":"MiR-218 inhibited growth and metabolism of human glioblastoma cells by directly targeting E2F2","volume":"35","author":"Zhang","year":"2015","journal-title":"Cell. Mol. Neurobiol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.3892\/or.2015.3986","article-title":"MicroRNA-204 inhibits proliferation, migration, invasion and epithelial-mesenchymal transition in osteosarcoma cells via targeting Sirtuin 1","volume":"34","author":"Shi","year":"2015","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.biopha.2016.05.049_bib0060","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s40001-014-0068-2","article-title":"Decreased expression and clinical significance of miR-148a in hepatocellular carcinoma tissues","volume":"19","author":"Pan","year":"2014","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.biopha.2016.05.049_bib0065","doi-asserted-by":"crossref","first-page":"1472","DOI":"10.1038\/labinvest.2011.99","article-title":"MicroRNA-148a is down-regulated in human pancreatic ductal adenocarcinomas and regulates cell survival by targeting CDC25B","volume":"91","author":"Liffers","year":"2011","journal-title":"Lab. Invest."},{"issue":"3","key":"10.1016\/j.biopha.2016.05.049_bib0070","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2015.3827","article-title":"MicroRNA-148a inhibits migration and invasion of ovarian cancer cells via targeting sphingosine-1-phosphate receptor 1","volume":"12","author":"Wen","year":"2015","journal-title":"Mol. Med. Rep."},{"issue":"3","key":"10.1016\/j.biopha.2016.05.049_bib0075","doi-asserted-by":"crossref","DOI":"10.3892\/mmr.2015.3826","article-title":"MicroRNA-148a inhibits the proliferation and promotes the paclitaxel-induced apoptosis of ovarian cancer cells by targeting PDIA3","volume":"12","author":"Zhao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.biopha.2016.05.049_bib0080","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1038\/nature02871","article-title":"The functions of animal microRNAs","volume":"431","author":"Ambros","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2016.05.049_bib0085","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1186\/s12885-015-1438-z","article-title":"MicroRNA-217 functions as a prognosis predictor and inhibits colorectal cancer cell proliferation and invasion via an AEG-1 dependent mechanism","volume":"15","author":"Wang","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2016.05.049_bib0090","first-page":"1705","article-title":"Prognostic significance and anti-proliferation effect of microRNA-365 in hepatocellular carcinoma","volume":"8","author":"Chen","year":"2015","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0095","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1186\/s13000-015-0257-5","article-title":"Decreased expression of microRNA-124 is an independent unfavorable prognostic factor for patients with breast cancer","volume":"10","author":"Dong","year":"2015","journal-title":"Diagn. Pathol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0100","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/cas.12330","article-title":"MicroRNA-148a is downregulated in gastric cancer, targets MMP7, and indicates tumor invasiveness and poor prognosis","volume":"105","author":"Sakamoto","year":"2014","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2016.05.049_bib0105","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s11010-013-1682-y","article-title":"MicroRNA-148a suppresses epithelial-to-mesenchymal transition by targeting ROCK1 in non-small cell lung cancer cells","volume":"380","author":"Li","year":"2013","journal-title":"Mol. Cell. Biochem."},{"key":"10.1016\/j.biopha.2016.05.049_bib0110","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1007\/s12032-014-0984-6","article-title":"MicroRNA-148b expression is decreased in hepatocellular carcinoma and associated with prognosis","volume":"31","author":"Zhang","year":"2014","journal-title":"Med. Oncol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0115","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1158\/0008-5472.CAN-13-1449","article-title":"microRNA-148a is a prognostic oncomiR that targets MIG6 and BIM to regulate EGFR and apoptosis in glioblastoma","volume":"74","author":"Kim","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2016.05.049_bib0120","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.mce.2014.03.006","article-title":"MicroRNAs as prognostic markers in ovarian cancer","volume":"390","author":"Llaurado","year":"2014","journal-title":"Mol. Cell. Endocrinol."},{"issue":"6","key":"10.1016\/j.biopha.2016.05.049_bib0125","doi-asserted-by":"crossref","DOI":"10.1007\/s13277-015-3138-3","article-title":"MicroRNA-200c and microRNA-141 as potential diagnostic and prognostic biomarkers for ovarian cancer","volume":"36","author":"Gao","year":"2015","journal-title":"Tumour Biol."},{"key":"10.1016\/j.biopha.2016.05.049_bib0130","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.canlet.2014.11.011","article-title":"miR-145, targeting high-mobility group A2, is a powerful predictor of patient outcome in ovarian carcinoma","volume":"356","author":"Kim","year":"2015","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2016.05.049_bib0135","doi-asserted-by":"crossref","first-page":"8595","DOI":"10.7314\/APJCP.2014.15.20.8595","article-title":"miR-200a overexpression in advanced ovarian carcinomas as a prognostic indicator","volume":"15","author":"Zhu","year":"2014","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"10.1016\/j.biopha.2016.05.049_bib0140","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.18632\/oncotarget.2963","article-title":"The BRCA1\/2-directed miRNA signature predicts a good prognosis in ovarian cancer patients with wild-type BRCA1\/2","volume":"6","author":"Gu","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2016.05.049_bib0145","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/07357907.2013.876646","article-title":"Sphingosine 1 phosphate: a potential molecular target for ovarian cancer therapy?","volume":"32","author":"Dai","year":"2014","journal-title":"Cancer Invest."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216300683?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332216300683?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T11:49:26Z","timestamp":1776944966000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332216300683"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":29,"alternative-id":["S0753332216300683"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2016.05.049","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Decreased expression of microRNA-148a predicts poor prognosis in ovarian cancer and associates with tumor growth and metastasis","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2016.05.049","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}